tiprankstipranks

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Scotiabank lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $74 from $75 and keeps an Outperform rating on the shares. The firm is impressed by the company’s regulatory and clinical execution in Q4, the analyst tells investors. Scotiabank believes Agios is well-equipped to accelerated growth of the Pyrukynd franchise and remains cautiously optimistic on mitapivat’s point of sickening.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue